Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Structure activity relationships of novel antiepileptic drugs.

Mittapalli GK, Roberts E.

Curr Med Chem. 2014;21(6):722-54. Review.

PMID:
24251563
2.

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B.

Epilepsia. 2016 Apr;57(4):538-48. doi: 10.1111/epi.13340. Epub 2016 Feb 26. Review.

PMID:
26920914
3.

The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.

Gunthorpe MJ, Large CH, Sankar R.

Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. Review.

4.

Diverse mechanisms of antiepileptic drugs in the development pipeline.

Rogawski MA.

Epilepsy Res. 2006 Jun;69(3):273-94. Epub 2006 Apr 18. Review.

5.

Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy.

Cosford ND, Meinke PT, Stauderman KA, Hess SD.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):81-104. Review.

PMID:
12769636
6.

AMPA receptors in epilepsy and as targets for antiepileptic drugs.

Rogawski MA, Donevan SD.

Adv Neurol. 1999;79:947-63. Review.

PMID:
10514878
7.

Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.

Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK.

Mol Pharmacol. 2000 Sep;58(3):591-600.

8.

New AMPA antagonists in epilepsy.

Russo E, Gitto R, Citraro R, Chimirri A, De Sarro G.

Expert Opin Investig Drugs. 2012 Sep;21(9):1371-89. doi: 10.1517/13543784.2012.705277. Epub 2012 Jul 13. Review.

PMID:
22788917
9.

Targeting SV2A for Discovery of Antiepileptic Drugs.

Kaminski RM, Gillard M, Klitgaard H.

In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012.

10.

New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels.

Rogawski MA, Bazil CW.

Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52. Review.

11.

Brivaracetam: a rational drug discovery success story.

Rogawski MA.

Br J Pharmacol. 2008 Aug;154(8):1555-7. doi: 10.1038/bjp.2008.221. Epub 2008 Jun 16.

12.

The discovery and development of perampanel for the treatment of epilepsy.

Hanada T.

Expert Opin Drug Discov. 2014 Apr;9(4):449-58. doi: 10.1517/17460441.2014.891580. Epub 2014 Feb 24. Review.

PMID:
24559052
13.

[Mechanism of action of antiepileptic drugs and new antiepileptic drugs].

Armijo JA, Adin J, Sánchez MB.

Rev Neurol. 2006 Oct 10;43 Suppl 1:S17-41. Review. Spanish.

14.

Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties.

Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B.

Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14.

15.

New antiepileptic drugs that are second generation to existing antiepileptic drugs.

Bialer M.

Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. Review.

PMID:
16732716
16.

New developments in the treatment of partial-onset epilepsy.

Besag FM, Patsalos PN.

Neuropsychiatr Dis Treat. 2012;8:455-64. doi: 10.2147/NDT.S25099. Epub 2012 Oct 17.

17.

N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.

Wickenden AD, Krajewski JL, London B, Wagoner PK, Wilson WA, Clark S, Roeloffs R, McNaughton-Smith G, Rigdon GC.

Mol Pharmacol. 2008 Mar;73(3):977-86. Epub 2007 Dec 18.

18.

Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.

Rektor I.

Expert Opin Pharmacother. 2013 Feb;14(2):225-35. doi: 10.1517/14656566.2013.754883. Epub 2012 Dec 23. Review.

PMID:
23259931
19.

Non-competitive AMPA antagonists of 2,3-benzodiazepine type.

Sólyom S, Tarnawa I.

Curr Pharm Des. 2002;8(10):913-39. Review.

PMID:
11945139
20.

Supplemental Content

Support Center